Objective It is to evaluate the efficacy and toxicity of paclitaxel Liposome comhined with oxaliplacin and capecitabine in the first-line chemotherapy of advanced gastric cancer. Methods The clinical data of 36 patients with advanced gastric cancer those treated with paclitaxel Liposome combined with oxaliplatin and capecitabine was analyzed retrospectively. Results The total effective rate was 61％ . The median time to progression ( MTTP ) and median survival time ( MST ) of advanced gastric cancer were 6. 8 months and 11. 3 months respectively. The common side-effects were hematological toxicities. The incidence of grade Ⅲ/Ⅳ leucopenia, neutropenia, anemia and thromhocytopenia were 14％ ,. 19％, 3％ and 0 respectively. Non-hematologic toxicity was fairly mild , majority were grade Ⅰ / Ⅱ . Conclusion Paclitaxel Liposome comhined with oxaliplatin and capecitahine as the first-line treatment in patients with advanced gastric cancer is safe and effective.%目的 评价紫杉醇脂质体联合奥沙利铂和卡培他滨一线治疗晚期胃癌的疗效和毒性.方法 回顾性分析36例接受紫杉醇脂质体联合奥沙利铂和卡培他滨化疗的晚期胃癌患者的临床资料.结果 总有效率为61%,中位疾病进展时间为6.8个月,中位生存时间为11.3个月.主要不良反应为血液学毒性,Ⅲ/Ⅳ级白细胞减少、中性粒细胞减少、贫血及血小板减少发生率分别为14%,19%,3%和0%;非血液学毒性较轻,多为Ⅰ/Ⅱ级.结论 紫杉醇脂质体联合奥沙利铂和卡培他滨治疗晚期胃癌安全、有效.
展开▼
